EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 370 filers reported holding EXELIXIS INC in Q3 2020. The put-call ratio across all filers is 2.74 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $38,699,147 | +62.7% | 1,771,128 | +42.3% | 0.03% | +65.0% |
| Q2 2023 | $23,778,841 | +15.0% | 1,244,314 | +16.8% | 0.02% | +11.1% |
| Q1 2023 | $20,683,801 | +19.8% | 1,065,626 | -1.0% | 0.02% | +20.0% |
| Q4 2022 | $17,265,440 | +48.2% | 1,076,399 | +44.9% | 0.02% | +36.4% |
| Q3 2022 | $11,648,000 | -6.0% | 742,844 | +24.8% | 0.01% | -8.3% |
| Q2 2022 | $12,394,000 | -10.1% | 595,286 | -2.1% | 0.01% | +9.1% |
| Q1 2022 | $13,785,000 | +14.8% | 608,078 | -7.4% | 0.01% | +37.5% |
| Q4 2021 | $12,008,000 | -18.2% | 656,870 | -5.4% | 0.01% | -27.3% |
| Q3 2021 | $14,684,000 | +15.9% | 694,617 | -0.1% | 0.01% | +10.0% |
| Q2 2021 | $12,671,000 | -22.7% | 695,420 | -4.1% | 0.01% | -16.7% |
| Q1 2021 | $16,384,000 | +8.2% | 725,273 | -3.8% | 0.01% | 0.0% |
| Q4 2020 | $15,137,000 | -11.5% | 754,189 | +7.8% | 0.01% | -20.0% |
| Q3 2020 | $17,104,000 | +5.8% | 699,532 | +2.7% | 0.02% | -6.2% |
| Q2 2020 | $16,171,000 | +40.0% | 681,180 | +1.5% | 0.02% | +14.3% |
| Q1 2020 | $11,553,000 | -8.3% | 670,914 | -6.2% | 0.01% | +27.3% |
| Q4 2019 | $12,600,000 | +5.6% | 715,070 | +6.0% | 0.01% | -8.3% |
| Q3 2019 | $11,935,000 | +20.6% | 674,889 | +45.7% | 0.01% | 0.0% |
| Q2 2019 | $9,898,000 | -2.9% | 463,192 | +8.2% | 0.01% | -7.7% |
| Q1 2019 | $10,193,000 | +25.1% | 428,266 | +3.4% | 0.01% | +18.2% |
| Q4 2018 | $8,147,000 | +2.6% | 414,188 | -7.6% | 0.01% | +10.0% |
| Q3 2018 | $7,944,000 | -25.8% | 448,300 | -9.9% | 0.01% | -33.3% |
| Q2 2018 | $10,708,000 | -25.7% | 497,590 | -23.5% | 0.02% | -28.6% |
| Q1 2018 | $14,413,000 | -31.8% | 650,703 | -6.3% | 0.02% | -27.6% |
| Q4 2017 | $21,119,000 | +31.4% | 694,705 | +4.7% | 0.03% | +20.8% |
| Q3 2017 | $16,078,000 | +1.9% | 663,539 | +3.6% | 0.02% | -4.0% |
| Q2 2017 | $15,773,000 | +224.9% | 640,400 | +185.9% | 0.02% | +212.5% |
| Q1 2017 | $4,854,000 | +40.8% | 224,000 | -3.1% | 0.01% | +33.3% |
| Q4 2016 | $3,447,000 | +8.7% | 231,200 | -6.7% | 0.01% | +20.0% |
| Q3 2016 | $3,171,000 | +61.4% | 247,900 | -1.5% | 0.01% | +66.7% |
| Q2 2016 | $1,965,000 | +94.2% | 251,600 | -0.6% | 0.00% | +50.0% |
| Q1 2016 | $1,012,000 | -40.3% | 253,100 | -15.7% | 0.00% | -33.3% |
| Q4 2015 | $1,694,000 | +16.0% | 300,300 | +15.4% | 0.00% | +50.0% |
| Q3 2015 | $1,460,000 | +99.7% | 260,300 | +33.8% | 0.00% | +100.0% |
| Q2 2015 | $731,000 | +111.3% | 194,500 | 0.0% | 0.00% | – |
| Q1 2015 | $346,000 | 0.0% | 194,500 | 0.0% | 0.00% | – |
| Q4 2014 | $346,000 | +16.1% | 194,500 | 0.0% | 0.00% | – |
| Q3 2014 | $298,000 | -54.8% | 194,500 | 0.0% | 0.00% | -100.0% |
| Q2 2014 | $659,000 | -9.1% | 194,500 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $725,000 | -38.1% | 194,500 | 0.0% | 0.00% | -50.0% |
| Q4 2013 | $1,171,000 | -0.6% | 194,500 | -3.9% | 0.00% | 0.0% |
| Q3 2013 | $1,178,000 | +94.1% | 202,352 | +51.4% | 0.00% | +100.0% |
| Q2 2013 | $607,000 | – | 133,652 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |